

# ASSESSMENT OF THE QUALITY OF LIFE OF PATIENTS WITH ALLERGIC RHINITIS

Ikramova Nargiza Alisher qizi  
Adizova Madinabonu Lazizjon qizi  
Muhammadiyeva Ismigul Jamshidovna  
Umbetova Jasmina Murat qizi  
Nasimova Sitora Otabek qizi  
Tashkent State Medical University

## Abstract

The relevance of this work is due to the high prevalence of allergic rhinitis (AR) and bronchial asthma (BA). AR affects 10% to 40% of the population, while BA affects an average of 5% to 10% of the population in various countries. Numerous epidemiological studies have demonstrated a close relationship between these conditions. Thus, 80-98% of patients with BA have AR, and up to 40-56% of patients with rhinitis have BA. It has been found that AR precedes BA in the majority of cases (32-64%) and is a risk factor for its development. AR is often underdiagnosed in clinical practice. The time from the onset of symptoms to diagnosis of AR is 4 to 8.5 years. In 2021, members of the WHO expert working group adopted the "Allergic Rhinitis and its Impact on Asthma" (ARIA) program, which identified the main challenges in the diagnosis and treatment of AR. The relationship between AR and asthma is the subject of intensive research. In recent years, three most likely mechanisms for this interaction have been identified: the shutdown of the physiological function of the nose, the rhinobronchial reflex, and the so-called "inflammatory" reflex. However, the condition of the lower respiratory tract in patients with AR without asthma remains poorly understood. Further research is needed to understand how AR and asthma influence each other's course and patients' quality of life.

## Introduction

### The Aim of the Work

To study the relationship between the upper and lower respiratory tract in patients with allergic rhinitis and bronchial asthma in order to optimize the treatment of these diseases.

### Research Objectives

To determine bronchial patency and bronchial hyperreactivity to acetylcholine in patients with allergic rhinitis without bronchial asthma. To study the content of hydrogen peroxide in exhaled air condensate in patients with allergic rhinitis, with and without clinical symptoms of bronchial asthma. To assess the impact of allergic rhinitis on the quality of life of patients with bronchial asthma and its course. To study the impact of bronchial asthma on the course of allergic rhinitis and the quality of life of patients with this disease. To study the effect of modern

antihistamines and nasal glucocorticoids on the course of allergic rhinitis and bronchial asthma. To evaluate the effect of inhaled glucocorticoids on the course of allergic rhinitis.

### Study Results

Subclinical lower respiratory tract inflammation has been demonstrated for the first time in patients with allergic rhinitis without asthma. It has been established for the first time that allergic rhinitis contributes to the severity of asthma, and asthma contributes to the severity of rhinitis. It has been shown for the first time that antihistamines and nasal glucocorticoids, by reducing the severity of allergic rhinitis symptoms, improve the quality of life in patients with concomitant asthma. It has been shown for the first time that inhaled steroids can reduce the severity of some allergic rhinitis symptoms. It has been shown that lower respiratory tract examination is necessary in patients with allergic rhinitis to detect asthma. The need for treating allergic rhinitis with modern antihistamines and nasal glucocorticoids to improve the course of concomitant asthma has been demonstrated.

Patients with allergic rhinitis without asthma have subclinical inflammation of the lower respiratory tract. The combination of allergic rhinitis and asthma adversely affects the course of each disease. Treatment of allergic rhinitis with modern antihistamines and nasal glucocorticoids improves the course of concomitant asthma. The inhaled glucocorticoid budesonide, prescribed to patients with asthma and allergic rhinitis, can reduce the severity of individual rhinitis symptoms. Bronchial asthma (BA) and allergic rhinitis (AR) are the most common conditions, accounting for a large share of overall morbidity and causes of disability among allergic diseases.

According to World Health Organization (WHO) statistics, hundreds of millions of people worldwide suffer from allergic rhinitis (AR), with approximately 300 million people suffering from asthma worldwide. Epidemiological studies predict that by 2025, the number of asthma patients will increase by another 100 million. Data from domestic epidemiological studies also indicate an increase in the prevalence of asthma. According to the Respiratory Society, approximately 7 million people currently suffer from asthma, but only 1 million are registered with pulmonologists. The prevalence of AR among the adult population, according to studies conducted using standardized international questionnaires, ranges from 3.4% to 10.6%. Official statistics on the prevalence of AR, based on patient visits, are tens of times lower than the actual values. Long-term epidemiological studies show a progressive increase in the number of people suffering from allergic rhinitis. The prevalence of allergic rhinitis varies from 12.7% to 24% in different regions. Bronchial asthma and allergic rhinitis are chronic diseases that require ongoing, lifelong treatment and preventive measures, which is accompanied by significant financial costs for the healthcare system, patients, their families, and society as a whole. In addition, the medical, social, and economic significance of asthma is associated with temporary loss of ability to work and physical activity of patients, disability, and asthma-related mortality. Economic losses caused by asthma exceed those of tuberculosis and HIV/AIDS combined. The mortality rate from asthma is of great importance, since it indirectly reflects the state of disease control. Worldwide, approximately 250,000 people out of 300 million people

with asthma die each year. In 2007, 3,333 people died from asthma, and the mortality rate was 2.3 per 100,000 population (in the USA - 0.4). In 50-80% of cases, asthma is combined with allergic rhinitis. These patients were significantly more likely than those with isolated asthma to have drug and food allergies, pollen sensitization, concomitant upper respiratory tract pathology, and a family history of allergic rhinitis. Most of these patients have uncontrolled asthma. The frequent combination of asthma and rhinitis suggests the concept of "one airway, one disease." Therefore, allergic rhinitis should be considered a risk factor for the development of one of the most severe allergic diseases—asthma.

Despite all the advances in asthma management, many patients still experience poor asthma control, and their quality of life remains low. Some researchers attribute this to irregular and untimely adherence to medical prescriptions, particularly for inhaled medications (IMS); only 15% of patients use their asthma medications correctly. Even in large cities and regional centers, the quality of asthma diagnosis and treatment in outpatient settings remains low. The increasing prevalence of uncontrolled asthma, in turn, increases the direct costs associated with expensive medical care, such as emergency medical care and inpatient treatment. In 2021, members of a WHO working group developed the ARIA program, which summarizes current understanding of allergic rhinitis, proposes a new classification of AR, highlights the relationship between AR and asthma, and the deterioration in quality of life in patients with AR. It also presents a methodology for primary, secondary, and tertiary AR prevention based on the principles of evidence-based medicine.

ARIA and GINA have developed a stepwise approach to achieving disease control, which for both AR and BA involves increasing the amount of therapy when disease control is insufficient and decreasing the amount of therapy (to the minimum necessary) when control is achieved. According to some data, only 50% of patients with a confirmed diagnosis of AR receive adequate antiallergic therapy. When AR and BA symptoms persist, the drugs of choice are intranasal and inhaled glucocorticosteroids, which have a potent anti-inflammatory effect, antileukotriene agonists (ALA), and long-acting B<sub>2</sub>-agonists (LABA), which have a round-the-clock bronchodilatory effect in BA. In cases where control is not achieved in patients with moderate to severe persistent BA using medium/high doses of ICS and LABA, then leukotriene receptor antagonists (LAA) are recommended to be added to the treatment in steps 3-4. ALS are also recommended for the treatment of AR.

By affecting two inflammatory pathways— prostacyclin and leukotriene —ICS and ALS, when administered simultaneously, have a complementary effect, allowing for a more pronounced anti-inflammatory and, consequently, clinical effect and improved quality of life in children and adults while reducing the ICS dose. Important compliance -enhancing advantages of ALS include its tablet form, convenient once-daily dosing, and good tolerability. The clinical efficacy of montelukast in patients with asthma and allergic rhinitis has been demonstrated in domestic studies. For the treatment of asthma, patients diagnosed with asthma receive free ILS under the "affordable drugs" program and "vital drugs" from regional and federal budgets. ALS are not included in the list of drugs received by patients under these programs and are unaffordable for most patients, limiting their widespread use. The clinical

efficacy of ALS in isolated BA, AR, and the combination of BA and AR has been well studied. However, the pharmacoeconomic aspects of combination therapy with ICS and ALS in BA combined with AR have been insufficiently studied. This may be useful for justifying the inclusion of this group of drugs in the list of medications for subsidized provision to patients with asthma. Thus, the high prevalence of AR and BA, the severity of the disease, often due to the combination of these diseases, insufficient control of AR and BA symptoms, and the associated significant financial losses to the state and individuals necessitate further epidemiological and clinical-economic studies on AR and BA. The anti-inflammatory effect of ALS in the upper and lower respiratory tract, potentiated by topical GCS, is an important means of increasing the effectiveness of treatment for patients with BA combined with AR and, possibly, a way to reduce treatment costs, which requires confirmation through clinical-economic analysis.

### Conclusions

The overall incidence rate does not reflect the actual number of patients with allergic rhinitis and bronchial asthma in the population: in 2022, the number of patients with AR in Lesnoy according to the data on consultations (overall incidence) was 164 times less, and the number of patients with bronchial asthma was 7 times less than according to the data on the prevalence of AR and BA, respectively. Mortality and morbidity rates caused by bronchial asthma tend to improve against the background of increasing availability of ALL for asthma patients: since 2010, primary disability has decreased to 0; since 2021, the number of emergency medical service calls has decreased by 1.5 times; In 2022, the number of hospitalizations decreased by 1.2 times, and asthma-related mortality dropped to 0. The prevalence of allergic rhinitis and bronchial asthma in 2012 was 17.1% and 8.9%, respectively. Women were 4.7 times more likely to have bronchial asthma and 1.8 times more likely to have allergic rhinitis than men. The prevalence of bronchial asthma has increased by 1.6 times over the past 10 years. The most significant risk factors for AR and BA were: having immediate relatives with asthma and allergies, and having pets, birds, and an aquarium with fish in the home. Clinical and allergological characteristics of patients with bronchial asthma identified in the population study differed from patients with bronchial asthma from the registry: in the population, patients with mild asthma (87.5%) were 7 times more common than with moderate and severe asthma (12.5%); atopic bronchial asthma prevailed in 73% of cases; household sensitization prevailed in 63% of patients with bronchial asthma; the proportion of asthma patients with concomitant allergic rhinitis and/or nasal polyposis was 48%. In the population, mild AR (66%) was 1.9 times more common than moderate asthma (34%); intermittent asthma was observed in 53% of cases, persistent asthma - in 47% of cases; pollen sensitization prevailed in 68% of patients with allergic rhinitis. The inclusion of montelukast in the background therapy of persistent bronchial asthma of moderate/severe course in combination with allergic rhinitis resulted in a decrease in rhinitis symptoms, a significant increase in the forced expiratory volume in the first second, the average number of days without asthma symptoms, a decrease in the need for topical adrenergic agonists, and improved asthma control with a 2-fold decrease in the dose of

topical glucocorticosteroids . In the structure of direct costs for the management of patients with BA in combination with AR, the share of expenses on outpatient drug therapy was 94.2-92.3%; the inclusion of leukotriene receptor antagonists in therapy reduced the costs of ALT by 16.4%, and direct costs in general by 21.2%. A pharmacoeconomic analysis using the cost/effectiveness method showed better dynamics (2.2 times) of reduction in direct costs per unit of effectiveness (asthma symptom-free days) in the treatment of patients with moderate to severe persistent asthma combined with allergic rhinitis with montelukast than in patients in the comparison group.

### Practical Recommendations

To optimize care for patients with AR and BA, it is recommended to conduct a study on the prevalence of allergic respiratory diseases over time. For the creation and maintenance of a registry of AR and BA patients, it is advisable (due to its accessibility and ease of management) to use a Microsoft spreadsheet program. Excel. To enhance the clinical and economic benefits of therapy in patients with moderate to severe asthma combined with allergic rhinitis, it is recommended to add ALS to topical glucocorticosteroids. When conducting pharmacoeconomic analysis, it is advisable to use the number of asthma-free days as the unit of effectiveness. To improve the availability of ALS for patients with asthma, it is recommended to include ALS in the subsidized drug provision program.

### References

1. Abduraimovna, A.D., Turg'unboyevna, Y.N. and Rustamovna, Q.S., 2023. QIZLARNI OILA VA JAMIYATDA O 'ZO 'RNINI TOPISHDA PSIXOLOGIK KO 'NIKMA VA MA'NAVIY YETUKLIKNI SHAKLLANTIRISH. *Scientific Impulse*, 1(7), pp.310-313.
2. Akhmadalievna, N., Nigmatullaeva, D., Kamilov, A., Hakimova, D., & Salomova, F. (2020). Comparative self-assessment of the teachers' health of higher education institutions of the republic of Uzbekistan. *International Journal of Advanced Science and Technology*, 29(5), 1353-1355.
3. DS, K. (2022). PREVALENCE OF ALLERGIC DISEASES IN CHILDREN UNDER HOT CLIMATIC CONDITIONS. In *Materials of International Scientific-Practical Conference. «Only English: Topical Issues of Healthcare»*.
4. Ibodullaevna, S. F., Rustamovna, K. S., Gairatovna, A. D., & Abdurakhmonovna, S. H. (2022). PREVALENCE AND RISK FACTORS OF ALLERGIC DISEASES IN CHILDREN IN HOT CLIMATIC CONDITIONS. *Art of Medicine. International Medical Scientific Journal*, 2(3).
5. Ikramova, N. A., & Axmedova, R. D. (2025, April). THE IMPACT OF ATMOSPHERIC AIR POLLUTION ON HUMAN HEALTH. In *The Conference Hub* (pp. 7-10).
6. Ikramova, N. A., & Axmedova, R. D. (2025, March). THE IMPACT OF ATMOSPHERIC ENVIRONMENTAL POLLUTION ON HUMAN HEALTH: THE ROLE OF MOTOR VEHICLES AND INDUSTRIAL EMISSIONS. *International Conference on Advance Research in Humanities, Applied Sciences and Education*.



7. Ikramova, N. A., Jalolov, N. N., Mirsagatova, M. R., Kasimova, K. T., Sadirova, M. K., & Sultonov, E. Y. (2025, April). AMBIENT TEMPERATURE AND THE RISK OF THERMOREGULATORY DISORDERS AMONG TRAFFIC POLICE OFFICERS: AN EPIDEMIOLOGICAL ANALYSIS. International Conference on Advance Research in Humanities, Applied Sciences and Education.
8. Ikramova, N. A., Mirsagatova, M. R., Jalolov, N. N., Kasimova, K. T., Sultonov, E. Y., & Sadirova, M. K. (2025, April). THE EFFECT OF THERMAL LOAD ON THE BODY OF OUTDOOR WORKERS: ANALYSIS BASED ON MEDICAL AND HYGIENIC INDICATORS. International Conference on Advance Research in Humanities, Applied Sciences and Education.
9. Ikramova, N. A., Sherqo'zieva, G. F., & Salomova, F. I. (2025). OZIQ-OVQAT MAHSULOTLARININING XAVFSIZLIGI MUAMMOLARI VA YECHIMLARI. *Медицинский журнал молодых ученых*, (13 (03)), 279-283.
10. Ikramova, N. A., Suyunov, M. Z., & Kholdarov, A. A. (2025, April). HYGIENIC ASSESSMENT OF PROFESSIONAL RISK FACTORS FOR ROAD PATROL EMPLOYEES IN HOT CLIMATE. In *The Conference Hub* (pp. 59-62).
11. Jalolov, N. N., & Ikramova, N. A. (2025, April). THE RELATIONSHIP BETWEEN AIR POLLUTION AND ARTERIAL HYPERTENSION. In *The Conference Hub* (pp. 169-173).
12. Jalolov, N. N., Sobirov, O. G., Kabilzhonova, S. R., & Imamova, A. O. (2023). The role of a healthy lifestyle in the prevention of myocardial infarction. *Neo Sci Peer Rev J*, 9, 8-14.
13. Jalolov, N. N., Umedova, M. E., & Ikramova, N. A. (2025, April). Occupational risk factors for workers operating in hot climates: the case of traffic police officers. International Conference on Advance Research in Humanities, Applied Sciences and Education.
14. Kobiljonova, S. H. THE ROLE OF SPORTS IN THE FORMATION OF A HEALTHY LIFESTYLE AMONG YOUNG PEOPLE Yuldasheva FU Tashkent Medical Academy, Uzbekistan Imamova AO.
15. Kobiljonova, S. R., & Jalolov, N. N. (2023). Reproductive and perinatal outcomes born by caesarean section.
16. Kobiljonova, S. R., Jalolov, N. N., Sharipova, S. A., & Mirsagatova, M. R. (2022). COMBINED SKIN AND RESPIRATORY MANIFESTATIONS OF FOOD ALLERGY IN CHILDREN.
17. Kobiljonova, S. R., Jalolov, N. N., Sharipova, S. A., & Tashmatova, G. A. (2023). Clinical and morphological features of gastroduodenitis in children with saline diathesis. *American Journal of Pedagogical and Educational Research*, 10, 35-41.
18. Kobiljonova, S. R., Jalolov, N. N., Sharipova, S. A., & Tashmatova, G. A. (2023). Clinical and morphological features of gastroduodenitis in children with saline diathesis. *American Journal of Pedagogical and Educational Research*, 10, 35-41.

19. Kobiljonova, S., Sultonov, E., Sultonova, D., Oblokulov, A., & Jalolov, N. (2023). CLINICAL MANIFESTATIONS OF GASTROINTESTINAL FOOD ALLERGY. *Евразийский журнал медицинских и естественных наук*, 3(5), 142-148.
20. Kosimova, K. T., Jalolov, N. N., & Ikramova, N. A. (2025, April). THE RELATIONSHIP BETWEEN AIR POLLUTION AND ARTERIAL HYPERTENSION. International Conference on Advance Research in Humanities, Applied Sciences and Education.
21. Kosimova, X. T., Ikramova, N. A., & Umedova, M. E. (2025). HAVONING IFLOSLANISHI VA ARTERIAL GIPERTENZIYA O 'RTASIDAGI ALOQADORLIK.
22. Niyazova, O. A., & Imamova, A. O. (2023). Improving the organization of the provision of medical services and the Digital environment. *European International Journal of Multidisciplinary Research and Management Studies*, 3(02), 41-46.
23. Otajonov, I., Shaykhova, G., Salomova, F., Kurbanova, K., Kurbonov, K., & Malokhat, N. (2020). Effectiveness of diet in experimental chronic kidney disease. *European Journal of Molecular and Clinical Medicine*, 7(2), 1097-1109.
24. Qosimova, X. T., Ikramova, N. A., Juraboyeva, D. N., & Mukhtorova, D. A. (2025, March). THE ADVERSE EFFECTS OF SMARTPHONES ON COGNITIVE ACTIVITY IN THE EDUCATIONAL PROCESS AND WAYS TO MITIGATE THEM. In *The Conference Hub* (pp. 76-79).
25. Rahimov, B. B., Salomova, F. I., Jalolov, N. N., Sultonov, E. Y., Qobiljonova Sh, R., & Obloqulov, A. G. (2023). O 'ZBEKISTON RESPUBLIKASI NAVOIY SHAHRI HAVO SIFATINI BAHOLASH: MUAMMOLAR VA YECHIM YOLLARI.
26. Sadullaeva, K. A., Sadirova, M. Q., Ikramova, N. A., & Sotivoldieva, S. A. (2025). EFFECT OF NUTRITION ON HEALTH OF SCHOOL STUDENTS.
27. Sadullaeva, K. A., Salomova, F. I., & Sadirova, M. K. (2023). CAR WASHES AS A SOURCE OF ENVIRONMENTAL POLLUTION. *Academia Repository*, 4(12), 340-344.
28. Sadullayeva, X. A., Salomova, F. I., & Mirsagatova, M. R. (2023). Problems of Pollution of Reservoirs in the Conditions of Uzbekistan. *Miasto Przyszłości*, 33, 102-106.
29. Sadullayeva, X. A., Salomova, F. I., & Sultonov, E. Y. (2023). Ochiq suv havzalari muhofazalash ob'ekti sifatida. In *V международная научно-практическая конференция «Современные достижения и перспективы развития охраны здоровья населения»*.
30. Sadullayeva, X. A., Salomova, F. I., Mirsagatova, M. R., & Kobiljonova Sh, R. (2023). Problems of Pollution of Reservoirs in the Conditions of Uzbekistan.
31. Sadullayeva, X. A., Salomova, F. I., Mirsagatova, M. R., & Kobiljonova Sh, R. (2023). Problems of Pollution of Reservoirs in the Conditions of Uzbekistan.
32. Salomova, F. I., Ahmadaliev, N. O., Sadullaeva, K. A., & Sherkuzieva, G. F. (2022). Dust storm and atmosphere air pollution in Uzbekistan.
33. Salomova, F. I., Akhmadaliev, N. O., Sharipova, S. A., & Abdukadirova, L. K. (2019). Social Portrait, Conditions, Lifestyle and Health of Universities Professors of The Republic of Uzbekistan in Modern Conditions. *Central Asian Journal of Medicine*, 2019(3), 93-103.

34. Salomova, F. I., Imamova, A. O., Mirshina, O. P., & Voronina, N. V. (2023). HYGIENIC ASSESSMENT OF THE CONDITIONS OF WATER USE OF THE POPULATION OF THE ARAL REGION. *Academic research in educational sciences*, 4(TMA Conference), 968-973.
35. Salomova, F. I., Mirrakhimova, M. K., & Kobilzhonova, S. R. (2022). Influence of environmental factors on the development of atopic dermatitis in children. In *European journal of science archives conferences series*.
36. Sharipova, S. A., & Ikramova, N. A. (2024). CONSEQUENCES OF NOT BREASTFEEDING FOR THE MOTHER AND INFANT.
37. Sharipova, S. A., Ikramova, N. A., Bahrriddinova, M. N., Toshpulatov, B. M., & Egamberdiyeva, Z. Z. (2025, March). SPECIFIC ASPECTS OF PREVENTION OF INFECTIOUS DISEASES. International Conference on Advance Research in Humanities, Applied Sciences and Education.
38. Sherko'zieva, G. F., Ikramova, N. A., Bakhrriddinova, M. N., Toshpulatov, B. M., Boysarieva, M. R., & Abdurashidova, D. J. & Rasulov, RS (2025). *ATMOSPHERIC AIR AND HEALTH*.
39. Sherko'zieva, G. F., Ikramova, N. A., Bakhrriddinova, M. N., Toshpulatov, B. M., Boysarieva, M. R., Abdurashidova, D. J., ... & Rasulov, R. S. (2025). *ATMOSPHERIC AIR AND HEALTH*.
40. Sherkuzieva, G. F. (2021). Сузиш бассейнлари сувининг ифлосланиш муаммоларининг замонавий ҳолати. *Молодой ученый*, (21), 624-627.
41. Sherkuzieva, G. F., Salomova, F. I., & Ikramova, N. A. (2025). IBN SINO'S FERTILIZERS ON MEDICINES IN THE" MEDICINE EPISTLE". *Web of Medicine: Journal of Medicine, Practice and Nursing*, 3(5), 257-260.
42. Sherkuzieva, G. F., Salomova, F. I., & Yuldasheva, F. U. (2023). Oziq ovqat qo'shimchalari va aholi salomatligi. 2023.«. O 'zbekistonda vinochilik va sanoat Uzmchiligi sohasining muammolari va Ularning innovatsion yechimlari» *Respublika ilmiy-texnikaviy konferensiya Ilmiy ishlar to 'plami*, 101-102.
43. Sherqo'ziyeva, G. F., Salomova, F. I., Sharipova, S. A., Yuldasheva, F. U., & Ikramova, N. A. (2025). Avtomobillashuv va uning ekologo-gigiyenik muammolari.
44. ShR, K., Mirrakhimova, M. H., & Sadullaeva, H. A. (2022). Prevalence and risk factors of bronchial asthma in children. *Journal of Theoretical and Clinical Medicine*, 2, 51-56.
45. Ахмадалиева, Н. О., Саломова, Ф. И., Садуллаева, К. А., Абдукадилова, Л. К., & Имамова, А. О. (2024). ИЗЪЯТО: Питание часто болеющих детей дошкольного возраста в организованных коллективах. В *BIO Web of Conferences* (т. 84, стр. 01011). *EDP Sciences*.
46. Жалолов, Н. Н., Нуриддинова, З. И., Кобилжонова, Ш. Р., & Имамова, А. О. (2022). *Главные факторы развития избыточного веса и ожирения у детей* (Doctoral dissertation, Doctoral dissertation, O 'zbekiston Respublikasi Sog 'liqni Saqlash vazirligi, Toshkent tibbiyot akademiyasi, Koryo universiteti "Atrof muhit muhofazasining dolzarb



- muammolari va inson salomatligi” xalqaro ishtirok bilan Respublika 9-ilmiy-amaliy anjumani materiallari to ‘plami 153 bet).
47. Кобилжонова, Ш. Р., Жалолов, Н. Н., & Журабоев, М. Т. (2022). Тугри овкатланиш спортчилар юкори натижалари гарови.
  48. Кобилжонова, Ш. Р., Миррахимова, М. Х., & Садуллаева, Х. А. (2022). Распространенность и факторы риска бронхиальной астмы у детей. *Журнал теоретической и клинической медицины*, (2), 51-56.
  49. Кобилжонова, Ш. Р., Миррахимова, М. Х., & Садуллаева, Х. А. (2022). Значение экологических факторов при бронхиальной астме у детей.
  50. Миррахимова, М. Х., Нишонбоева, Н. Ю., & Кобилжонова, Ш. Р. (2022). Атопик дерматит билан касалланган болаларда панкреатик етишмовчиликни коррекциялаш.
  51. Рахимов, Б. Б., Саломова, Ф. И., Жалолов, Н. Н., Султонов, Э. Ю., & Облакулов, А. Г. (2023). Оценка качества атмосферного воздуха в городе навои, республика Узбекистан: проблемы и решения. In *Сборник трудов по материалам Международной научно-практической конференции*.
  52. Садуллаева, Х. А., Саломова, Ф. И., Мирсагатова, М. Р., & Кобилжонова, С. Р. (2023). Проблемы загрязнения водоемов в условиях Узбекистана.
  53. Саломова, Ф. И. (2008). Особенности физического развития школьников с нарушениями осанки. *Вестник Санкт-Петербургской государственной медицинской академии им. ИИ Мечникова*, (4), 48-50.
  54. Саломова, Ф. И., Садуллаева, Х. А., Миррахимова, М. Х., Кобилжонова, Ш. Р., & Абатова, Н. П. (2023). Загрязнение окружающей среды и состояние здоровья населения. *Yosh olimlar tibbiyot jurnali*, 1(5), 163-166.
  55. Саломова, Ф. И., Шеркушева, Г. Ф., Салуллаева, Х. А., Султанов, Э. Ё., & Облокулов, Л. Г. (2023). Загрязнение атмосферного воздуха города алмалык. *Медицинский журнал молодых ученых*, 5(01), 142-146.
  56. Саломова, Ф., Садуллаева, Х., & Кобилжонова, Ш. (2022). Гигиеническая оценка риска развития аллергических заболеваний кожи у детского населения. Актуальные вопросы профилактики стоматологических заболеваний и детской стоматологии, 1(01), 88-91.